Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate

Introduction. The complete hematologic response is an integral part to achieve the complete cytogenetic response target and the major molecular response of imatinib mesylate therapy, although it does not determine the prognosis. The complete hematologic response in Indonesia is lower than in the wor...

Full description

Bibliographic Details
Main Authors: Ikhwan Rinaldi, Ary Harryanto Reksodiputro
Format: Article
Language:Indonesian
Published: Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo Hospital 2020-09-01
Series:Jurnal Penyakit Dalam Indonesia
Subjects:
Online Access:http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/461/245